Type of prostate cancer-Adenocarcinoma Posts on Medivizor
Navigation Menu

Type of prostate cancer-Adenocarcinoma Posts on Medivizor

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Read More

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Posted by on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients. Some...

Read More

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Posted by on Dec 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...

Read More

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Posted by on Nov 14, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical,...

Read More

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Posted by on Oct 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to...

Read More

Comparing the outcomes between prostate surgery and different types of radiotherapy in older patients with prostate cancer.

Comparing the outcomes between prostate surgery and different types of radiotherapy in older patients with prostate cancer.

Posted by on Sep 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients. Some background...

Read More

Comparing outcomes for prostate surgery versus radiation therapy for localized prostate cancer

Comparing outcomes for prostate surgery versus radiation therapy for localized prostate cancer

Posted by on Jul 31, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to compare the effectiveness of surgery versus radiation therapy for patients with high-grade localized prostate cancer (PCa). The study concluded that surgery was associated with improved survival compared to radiation therapy in these patients. Some background Prostate cancer (PCa) is the second most common...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Posted by on Jun 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP. Some background Localized prostate cancer (PCa)...

Read More

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Posted by on May 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...

Read More

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More